Atria Investments Inc Takes Position in Dynavax Technologies Corporation $DVAX

Atria Investments Inc purchased a new position in Dynavax Technologies Corporation (NASDAQ:DVAX) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 18,695 shares of the biopharmaceutical company’s stock, valued at approximately $185,000.

Other hedge funds also recently bought and sold shares of the company. ELCO Management Co. LLC bought a new stake in shares of Dynavax Technologies in the 2nd quarter worth about $168,000. Mizuho Markets Americas LLC increased its stake in Dynavax Technologies by 9.0% during the second quarter. Mizuho Markets Americas LLC now owns 304,143 shares of the biopharmaceutical company’s stock worth $3,017,000 after acquiring an additional 25,000 shares during the last quarter. Peregrine Capital Management LLC raised its position in Dynavax Technologies by 1.8% during the second quarter. Peregrine Capital Management LLC now owns 688,896 shares of the biopharmaceutical company’s stock valued at $6,834,000 after purchasing an additional 11,878 shares during the period. Y Intercept Hong Kong Ltd bought a new stake in shares of Dynavax Technologies in the 2nd quarter valued at approximately $1,381,000. Finally, AlphaQuest LLC boosted its holdings in shares of Dynavax Technologies by 50.2% in the 2nd quarter. AlphaQuest LLC now owns 82,499 shares of the biopharmaceutical company’s stock worth $818,000 after purchasing an additional 27,579 shares during the period. Hedge funds and other institutional investors own 96.96% of the company’s stock.

Insider Activity

In other news, Director Scott Dunseth Myers purchased 3,800 shares of the company’s stock in a transaction dated Friday, August 22nd. The shares were acquired at an average price of $10.82 per share, with a total value of $41,116.00. Following the transaction, the director owned 35,004 shares of the company’s stock, valued at $378,743.28. This represents a 12.18% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 2.98% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently weighed in on DVAX. JMP Securities restated a “market outperform” rating and set a $32.00 price target on shares of Dynavax Technologies in a report on Friday, August 22nd. Wall Street Zen upgraded shares of Dynavax Technologies from a “hold” rating to a “buy” rating in a report on Saturday, August 9th. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of Dynavax Technologies in a report on Wednesday, October 8th. Three equities research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $24.33.

Dynavax Technologies Price Performance

Shares of DVAX stock opened at $11.16 on Friday. The company has a market capitalization of $1.31 billion, a P/E ratio of -24.26 and a beta of 1.09. The company’s 50-day simple moving average is $10.11 and its two-hundred day simple moving average is $10.30. Dynavax Technologies Corporation has a one year low of $9.20 and a one year high of $14.63. The company has a debt-to-equity ratio of 0.45, a current ratio of 6.65 and a quick ratio of 6.01.

Dynavax Technologies (NASDAQ:DVAX) last announced its quarterly earnings results on Wednesday, November 5th. The biopharmaceutical company reported $0.21 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.14 by $0.07. The firm had revenue of $94.88 million during the quarter, compared to analyst estimates of $94.00 million. Dynavax Technologies had a positive return on equity of 5.10% and a negative net margin of 16.67%. As a group, equities analysts anticipate that Dynavax Technologies Corporation will post 0.32 EPS for the current year.

Dynavax Technologies Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.